Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England

Journal of Dermatological Treatment

Volumn 25, Issue 1, 2014, Pages 67-72

  Khalid, Javaria Mona ^a   Fox, Kathleen M ^b   Globe, Gary ^c   Maguire, Andrew ^a   Chau, Dina ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

Biologic therapy; Dose intensification; PASI score; Psoriasis; Switching; Therapy discontinuation

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; BIOLOGICAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GUTTATE PSORIASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; THERAPY EFFECT; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; BIOLOGICAL PRODUCTS; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84890500184     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.768762     Document Type: Article

References (23)

1. Conway P, Currie CJ. Descriptive epidemiology of hospitalisation for psoriasis. Curr Med Res Opin. 2008;24:3487-3491.
2. Gelfand JM,WeinsteinR,Porter SB, NeimannAL, Berlin JA,MargolisDJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537-1541.
3. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143: 1559-1565.
4. Brazzelli V, Carugno A, Alborghetti A, Grasso V, Cananzi R, Fornara L, et al. Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol. 2012;26:1354-1359.
5. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA. Psoriasis of early and late onset: a clinical and epidemiological study from Spain. J Am Acad Dermatol. 2002;46:867-873.
6. Buesch K, Chapnick J, Gupta S, Bergemann R. Psoriasis in the EU: prevalence, health care resource utilization, and out-of-pocket costs. J Am Acad Dermatol. 2009;61:abstract 1101.
7. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216:366-372.
8. National Health System. Psoriasis. Available from www.nhs.uk/Conditions/ Psoriasis/Pages/NICE.aspx.cited 3 March 2012.
9. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJG, Chandler DA, et al. British Association of Dermatologists' guidelines of biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161: 987-1019.
10. British National Formulary. Edition 59. Available from www.bnf.org. cited 11 November 2011.
11. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatol Treat. 2013;24:64-69.
12. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091-1096.
13. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148: 487-494.
14. Laws PM, Downs AM, Parslew R, Dever B, Smith CH, Barker JN, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol. 2012;166:189-195.
15. Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatol Treat. 2013;24:25-33.
16. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;142:185-191.
17. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-867.
18. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 103: etanercept and efalizumab for the treatment of adults with psoriasis. 2006. Available from www.nice.org. uk/TA103.
19. Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997-1035.
20. Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate and severe psoriasis. Br J Dermatol. 2010;163:807-816.
21. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2009;160:162-169.
22. Bewley A, Cerio R, Clement M, Hunt S, Lucke T, Ratnavel R, et al. Current application of National Institute for Health and Clinical Excellence (NICE) guidance in the management of patients with severe psoriasis: a clinical audit against NICE guidance in seven National Health Service specialist dermatology units in England. Clin Exp Dermatol. 2011;36:602-606.
23. Van Lumig PPM, van de Kerkhof PCM, Boezeman JBM, Driessen RJB, de Jong EMGJ. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients. J Europ Acad Dermatol Vener. 2012;doi:10.1111/j.1468- 3083.2012.04496.x.